DNAJB1-PRKACA peptide vaccine
Sponsors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Conditions
Fibrolamellar Hepatocellular Carcinoma (FLC)Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
Phase 1
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
RecruitingNCT04248569
Start: 2020-04-20End: 2034-03-01Target: 56Updated: 2025-12-03
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Not yet recruitingNCT07430202
Start: 2026-09-01End: 2030-09-01Target: 27Updated: 2026-08-25